Effect of Evolocumab on Vascular Function

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT03626831

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03626831
Other papers using this trial's data
  • Endothelial function in high-risk patients with ezetimibe therapy Journal of clinical lipidology, 2025 DOI, PubMed 40813220

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03626831. Randomized; triple masking; primary purpose treatment. Start 2019-04-04 (actual); primary completion 2021-04-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Evolocumab on Vascular Function
Acronym
EVO
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Evolocumab Prefilled Syringe
Intervention (Drug)
Placebos
Lead sponsor
University of Erlangen-Nürnberg Medical School (class: other)

Record details

Record id
cardio:ct-nct03626831
Content hash
f040e645112af5c44ed221058611a94c37639299c1a008666e88dfb2da640c36